Trastuzumab containing regimens for early breast cancer-Reference-Cited by-同舟云学术

Trastuzumab containing regimens for early breast cancer

Published:2012-04-18 Issue:2 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Moja Lorenzo¹,Tagliabue Ludovica²,Balduzzi Sara³,Parmelli Elena⁴,Pistotti Vanna⁵,Guarneri Valentina⁶,D'Amico Roberto³

Affiliation:

1. Department of Biomedical Sciences for Health; University of Milan; Milan Italy

2. Medical Staff Directory; San Luca Hospital, Auxologic Institute; Milan Italy

3. Cochrane Italy, Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy

4. Department of Epidemiology; Lazio Regional Health Service - ASL Roma1; Rome Italy

5. Cochrane Italy and IRCCS Mario Negri Institute for Pharmacological Research; Milan Italy

6. Department of Surgery, Oncology and Gastroenterology; University of Padova, Istituto Oncologico Veneto IRCCS; Padova Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006243.pub2/fullpdf

Reference70 articles.

1. Doxorubicin and cyclophosphamide plus paclitaxel with or without trastuzumab in treating women with node-positive beast cancer that overexpresses HER2 www.clinicaltrials.gov

2. Perez EA Ramond EH Suman VJ Jeong J Davidson NE Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proceedings of ASCO Meeting; 2007; Chicago, USA. In: Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings 2007:512

3. Rastogi P Jeong J Geyer CE Costantino JP Romond EH Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)-->paclitaxel (T) vs AC-->T with trastuzumab (H). Proceedings of ASCO Meeting; 2007; Chicago, USA. In: Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings 2007:513

4. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;New England Journal of Medicine,2005

5. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31;Tan-Chiu;Journal of Clinical Oncology,2005

Cited by 460 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a reliable cell-based reporter gene assay to measure the bioactivity of anti-HER2 therapeutic antibodies;Journal of Pharmaceutical and Biomedical Analysis;2024-08

2. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

3. New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?;Cancers;2024-07-05

4. Breast cancer treatment and its impact on survival in Morocco: a study over a decade;BMC Cancer;2024-07-01

5. Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia;Cancers;2024-06-25